<DOC>
	<DOCNO>NCT00002380</DOCNO>
	<brief_summary>To determine pharmacokinetic property , tolerance safety 2 formulation saquinavir , give combination 2 nucleoside antiretroviral drug ( part 1 ) combination nelfinavir nucleoside antiretroviral drug ( part 2 ) , HIV-infected infant child .</brief_summary>
	<brief_title>The Safety Effectiveness Two Forms Saquinavir Combined With Other Anti-HIV Drugs HIV-Infected Infants Children</brief_title>
	<detailed_description>This Phase I/II study conduct 2 part last least 24 week . Pharmacokinetics safety data part 1 , treatment regimen contain saquinavir nucleoside antiretrovirals , collect 8 week proceed part 2 . During first 8 week , pharmacokinetic data analyze allow dose adjustment individual patient confirm start dose estimate part 2 . In addition , safety data review ensure saquinavir well tolerate nucleoside antiretrovirals combine second protease inhibitor . In part 2 , saquinavir combine nelfinavir , protease inhibitor recently approve use child . The pharmacokinetics safety profile drug combination determine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection accord standard definition employ Pediatric AIDS Clinical Trials Group . Laboratory evidence immunosuppression ( Centers Disease Control Prevention [ CDC ] categories 2 3 ) , symptomatic HIV disease ( CDC categories A , B , C ) . At least 4 patient ( 2 part 1 2 ) enrol three age stratum : 6 month 2 year ; great 2 year 6 year ; great 6 year 13 year . NOTE : For purpose analysis , patient stratify age . 1 . Patients must protease inhibitor therapy naive . Antiretroviral agent prescribe investigator . Biologic response modifier ( erythropoietin , GCSF , short course [ &lt; 14 day ] corticosteroid , intravenous immune globulin ) . Other investigational drug . Drugs know significantly interact saquinavir and/or nelfinavir . Patients must protease inhibitor therapy naive .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>